Common Stock, $0.001 par value per share
- Symbol
- HURA
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
TuHURA Biosciences, Inc.
HURANASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 14, 2026, TuHURA Biosciences, Inc. issued a press release reporting its financial results for the three months ended June 30, 2026, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.…
Press release in this filing
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update →Company context
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer. TuHURA’s lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
Current securities
Recent company filings
- Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementOct 16, 2026
- Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementSep 24, 2026
- Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementSep 17, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 17, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 16, 2026
Registered securities in this filing
TuHURA Biosciences, Inc./NV · 8-K · Filed 2026-08-14
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02
Results of Operations and Financial Condition.
On August 14, 2026, TuHURA Biosciences, Inc. issued a press release reporting its financial results for the three months ended June 30, 2026, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
The information contained in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.
Filed exhibits (1)
EX-99.1 2 hura-ex99_1.htm EX-99.1 EX-99.1 TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update TAMPA, Fla., August 14, 2026 -- TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended June 30, 2026, and provided a corporate update. “We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year,” said Dr. James Bianco, President and CEO of TuHURA Biosciences. “In the second half, we anticipate receiving safe-to-proceed feedback from FDA and to initiating our Phase 1b/2 trial of VISTA in mutNPM1 r/r AML, initiating our in vivo POC studies for MDSC Inhibitors (Bi-specific antibody drug conjugates (ADCs)), potentially receiving orphan drug designation in Merkel cell carcinoma (MCC) for IFx-2.0, and potentially receiving orphan drug designation in AML for TBS-2025. The recent $50 million term credit facility made avail…
Open exhibit ↗